Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Retained Earnings came in at $1.1 billion in Q2 2026, up 8.06% YoY from $989.8 million in Q2 2025, and up 2.27% on a QoQ basis from $1.0 billion in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Retained Earnings data on file, last reported at $1.1 billion in Q2 2026.
- Quarterly Retained Earnings rose 8.06% year-over-year to $1.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (up 8.06% YoY) and the FY2025 annual result came in at $1.0 billion, up 7.3% from the prior year.
- Retained Earnings grew to $1.1 billion in Q2 2026, from $1.0 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.1 billion in Q2 2026 to a low of $866.9 million in Q1 2022.
- A 5-year average of $945.5 million and a median of $931.2 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings climbed 3.07% — and 2026, when it increased 8.06%.
- Tracing KNSA's Retained Earnings over 5 years: stood at $888.1 million in 2022, then grew by 3.23% to $916.8 million in 2023, then increased by 4.69% to $959.7 million in 2024, then increased by 7.3% to $1.0 billion in 2025, then rose by 3.87% to $1.1 billion in 2026.
- The last three Retained Earnings figures came in at $1.1 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.57 Bn | 220.03 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Bn |
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 1.01 Bn |
| Jun 30, 2025 | 989.81 Mn |
| Mar 31, 2025 | 970.24 Mn |
| Dec 31, 2024 | 959.72 Mn |
| Sep 30, 2024 | 949.28 Mn |
| Jun 30, 2024 | 934.77 Mn |
| Mar 31, 2024 | 927.58 Mn |
| Dec 31, 2023 | 916.76 Mn |
| Sep 30, 2023 | 908.30 Mn |
| Jun 30, 2023 | 900.96 Mn |
| Mar 31, 2023 | 894.33 Mn |
| Dec 31, 2022 | 888.12 Mn |
| Sep 30, 2022 | 880.55 Mn |
| Jun 30, 2022 | 874.15 Mn |
| Mar 31, 2022 | 866.94 Mn |
| Dec 31, 2021 | 860.48 Mn |
| Sep 30, 2021 | 853.14 Mn |